Financial reports
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
20 Mar 23
10-K
2022 FY
Annual report
10 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
9 Mar 22
Current reports
8-K
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
11 Apr 24
8-K
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
28 Mar 24
8-K
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
25 Mar 24
8-K
Other Events
7 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
8-K
Lipocine to Present at 36th Annual Roth Conference
6 Mar 24
8-K
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
12 Feb 24
8-K
Lipocine and Verity Pharma Enter into License Agreement
18 Jan 24
8-K
Other Events
8 Jan 24
8-K
Lipocine to Present at Biotech Showcase 2024
19 Dec 23
Registration and prospectus
S-3/A
Shelf registration (amended)
23 Apr 24
S-3
Shelf registration
22 Nov 23
424B5
Prospectus supplement for primary offering
3 Apr 23
8-A12G
Registration of securities
10 Mar 23
424B5
Prospectus supplement for primary offering
27 Jan 21
424B5
Prospectus supplement for primary offering
25 Jan 21
S-3
Shelf registration
13 Nov 20
424B5
Prospectus supplement for primary offering
21 Aug 20
424B5
Prospectus supplement for primary offering
6 Aug 20
S-8
Registration of securities for employees
30 Jul 20
Proxies
DEF 14A
Definitive proxy
23 Apr 24
DEF 14A
Definitive proxy
27 Mar 23
PRE 14A
Preliminary proxy
17 Mar 23
DEF 14A
Definitive proxy
22 Apr 22
PRE 14A
Preliminary proxy
12 Apr 22
DEF 14A
Definitive proxy
27 Apr 21
PRE 14A
Preliminary proxy
9 Apr 21
PX14A6G
Letter to shareholders
20 May 20
DEF 14A
Definitive proxy
28 Apr 20
PX14A6G
Letter to shareholders
22 May 19
Other
EFFECT
Notice of effectiveness
26 Apr 24
EFFECT
Notice of effectiveness
24 Nov 20
CORRESP
Correspondence with SEC
20 Nov 20
UPLOAD
Letter from SEC
20 Nov 20
EFFECT
Notice of effectiveness
21 Nov 17
CORRESP
Correspondence with SEC
17 Nov 17
CORRESP
Correspondence with SEC
9 Nov 17
CORRESP
Correspondence with SEC
8 Nov 17
UPLOAD
Letter from SEC
24 Oct 17
CT ORDER
Confidential treatment order
26 Jul 16